These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Molecular basis of antigenic variation in the picornaviruses. Brown F Ann N Y Acad Sci; 1980; 354():202-18. PubMed ID: 6164329 [No Abstract] [Full Text] [Related]
4. [Inactivated vaccines against rhinopneumonitis in horses]. Tatarov G; Khristov S; Martinov S; Gergov P; Khristova V Vet Med Nauki; 1981; 18(4):3-9. PubMed ID: 6274082 [TBL] [Abstract][Full Text] [Related]
5. Molecular epidemiology of duck hepatitis a virus types 1 and 3 in China, 2010-2015. Wen X; Zhu D; Cheng A; Wang M; Chen S; Jia R; Liu M; Sun K; Zhao X; Yang Q; Wu Y; Chen X Transbound Emerg Dis; 2018 Feb; 65(1):10-15. PubMed ID: 29076646 [TBL] [Abstract][Full Text] [Related]
6. Modern approaches to live virus vaccines. Norrby E Adv Vet Sci Comp Med; 1989; 33():249-70. PubMed ID: 2494845 [No Abstract] [Full Text] [Related]
7. Strategy for construction of live picornavirus vaccines. Nomoto A; Iizuka N; Kohara M; Arita M Vaccine; 1988 Apr; 6(2):134-7. PubMed ID: 2838985 [TBL] [Abstract][Full Text] [Related]
8. [Molecular biology of paramyxoviruses and its significance for the development of vaccines]. Scheid A Internist (Berl); 1985 Feb; 26(2):98-102. PubMed ID: 3884533 [No Abstract] [Full Text] [Related]
9. Antigenic conservation and divergence between the viral-specific proteins of poliovirus type 1 and various picornaviruses. Emini EA; Schleif WA; Colonno RJ; Wimmer E Virology; 1985 Jan; 140(1):13-20. PubMed ID: 2981447 [TBL] [Abstract][Full Text] [Related]
10. Polymerase Mechanism-Based Method of Viral Attenuation. Lee CA; August A; Arnold JJ; Cameron CE Methods Mol Biol; 2016; 1349():83-104. PubMed ID: 26458831 [TBL] [Abstract][Full Text] [Related]
11. Recent developments with live-attenuated recombinant paramyxovirus vaccines. Le Bayon JC; Lina B; Rosa-Calatrava M; Boivin G Rev Med Virol; 2013 Jan; 23(1):15-34. PubMed ID: 22570186 [TBL] [Abstract][Full Text] [Related]
13. [Viral vaccines produced by gene technology and synthesis]. Hess RG Tierarztl Prax; 1986; 14(1):9-14. PubMed ID: 2424142 [TBL] [Abstract][Full Text] [Related]
14. Attenuated reovirus type 3 strains generated by selection of haemagglutinin antigenic variants. Spriggs DR; Fields BN Nature; 1982 May; 297(5861):68-70. PubMed ID: 6175910 [No Abstract] [Full Text] [Related]
15. Current status of dengue vaccines and prospects for the future. Bancroft WH P R Health Sci J; 1987 Apr; 6(1):23-6. PubMed ID: 3615797 [TBL] [Abstract][Full Text] [Related]
16. Polyprotein processing in picornavirus replication. Kräusslich HG; Nicklin MJ; Lee CK; Wimmer E Biochimie; 1988 Jan; 70(1):119-30. PubMed ID: 2840974 [TBL] [Abstract][Full Text] [Related]
18. [Replication of picornaviruses]. Nomoto A Uirusu; 1982 Jun; 32(1):1-15. PubMed ID: 6753323 [No Abstract] [Full Text] [Related]
19. Immune response to rotavirus polypeptides after vaccination with heterologous rotavirus vaccines (RIT 4237, RRV-1). Svensson L; Sheshberadaran H; Vesikari T; Norrby E; Wadell G J Gen Virol; 1987 Jul; 68 ( Pt 7)():1993-9. PubMed ID: 3037019 [TBL] [Abstract][Full Text] [Related]
20. New picornavirus vaccines for hepatitis A, and lessons from the control of poliomyelitis by the prototype picornavirus vaccines. Melnick JL Prog Med Virol; 1990; 37():47-55. PubMed ID: 2173848 [No Abstract] [Full Text] [Related] [Next] [New Search]